Talk:Aerie Pharmaceuticals

/* Edit Request */ new section
Edit request due to conflict of interest. Aerie Pharma is a client.

Edits to be implemented in the shaded right-hand box:

1. Change “Headquarters” to: Durham, North Carolina

2. Update “Industry” to: Pharmaceuticals, Ophthalmology

3. Add Founders entry and list the following as founders: David L. Epstein, M.D. Casey C. Kopczynski, Ph.D.

SKM.SamBrown (talk) 14:59, 15 December 2021 (UTC)


 * ✅ Happy Editing-- IAm Chaos  23:59, 20 March 2022 (UTC)

SKM.SamBrown

/* Edit Request */ new section
Edit request due to conflict of interest. Aerie Pharma is a client.

/* Edit Request */ new section
Promotional Tone Needs to Be Resolved

Edit request due to conflict of interest. Aerie Pharma is a client.

Since the April 2022 updates, this page has had a warning, "This article contains text that is written in a promotional tone. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (April 2022) (Learn how and when to remove this template message)."

Can we get this updated?

Sources to consider: https://aeriepharma.com/ https://finance.yahoo.com/quote/AERI/ https://www.cnbc.com/quotes/AERI https://www.annualreports.com/Company/aerie-pharmaceuticals-inc https://www.businesswire.com/portal/site/home/index.jsp?epi-content=MY_COMPANIES_CHART&symbol=AERI

SKM.SamBrown

/* Edit Request */ new section
Edit request due to conflict of interest. Aerie Pharma is a client.

Since the April 2022 updates, this page has had a warning, "This article contains text that is written in a promotional tone. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (April 2022) (Learn how and when to remove this template message)."

Can we get this updated?

Sources to consider: https://aeriepharma.com/ https://finance.yahoo.com/quote/AERI/ https://www.cnbc.com/quotes/AERI https://www.annualreports.com/Company/aerie-pharmaceuticals-inc https://www.businesswire.com/portal/site/home/index.jsp?epi-content=MY_COMPANIES_CHART&symbol=AERI

SKM.SamBrown

/* Edit Request */ new section
Would like to ADD the executive team to the page (in the side box).

Senior Executive Team: Raj Kannan - Chief Executive Officer Gary Sternberg, MD, MBA - Chief Medical Officer Casey C. Kopczynski, PhD - Chief Innovation Officer, Head of Research and External Innovation Peter Lang - Chief Financial Officer Michelle Senchyna, PhD - Head of Clinical Development and Operations Marvin Garrett - Head of Regulatory Affairs & Quality Assurance Craig Skenes - Head of Business Development John W. LaRocca, Esq - General Counsel Ken Ruettimann, PhD - Head of Manufacturing Wanda Francies - Head of Human Resources

SKM.SamBrown (talk) 17:47, 6 July 2022 (UTC)

Since the April 2022 updates, this page has had a warning, "This article contains text that is written in a promotional tone. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (April 2022) (Learn how and when to remove this template message)."

Can someone update the page to include more information?

Additional sources to consider: https://aeriepharma.com/ https://finance.yahoo.com/quote/AERI/ https://www.cnbc.com/quotes/AERI https://www.annualreports.com/Company/aerie-pharmaceuticals-inc https://www.businesswire.com/portal/site/home/index.jsp?epi-content=MY_COMPANIES_CHART&symbol=AERI

SKM.SamBrown (talk) 17:49, 6 July 2022 (UTC)

Incorrect spelling needs to be resolved - it should say "Ophthalmology" in the INDUSTRY section.

Replace "Opthamology" with "Ophthalmology"

SKM.SamBrown (talk) 17:54, 6 July 2022 (UTC)

Edit Request to Add Section: About/Type of Company:
Aerie Pharmaceuticals was founded in 2005 by Dr. David Epstein, M.D., MMM [1943-2014], a well-known and widely respected ophthalmologist who dedicated his clinical work to unraveling the mysteries of glaucoma. (https://theophthalmologist.com/power-list/2018/aerie-pharmaceuticals-inc) As a publicly traded, clinical-stage pharmaceutical company, Aerie is focused on the discovery, development and commercialization of therapies to treat glaucoma, dry eye, diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD). (https://www.reuters.com/markets/companies/AERI.OQ/) SKM.SamBrown (talk) 17:46, 30 August 2022 (UTC)

Edit Request to Add Section: Unique Glaucoma Technology:
AR-12286 is a highly selective Rho kinase (ROCK) inhibitor designed to lower intraocular pressure by improving outflow of fluid via the trabecular pathway with the potential of restoring normal function. (https://pubmed.ncbi.nlm.nih.gov/21794845/) This class of compounds acts directly on diseased tissue, the trabecular meshwork (TM), which undergoes pathological changes in patients with primary open-angle glaucoma. An altered TM morphology eventually restricts the drainage of fluid from the eye, which causes an increase in intraocular pressure and ultimately damage to the optic nerve. ROCK inhibitors return the TM to a state that allows normal drainage of ocular fluid and thereby reduces pressure in the eye. (https://bjo.bmj.com/content/97/5/567) SKM.SamBrown (talk) 17:46, 30 August 2022 (UTC)

Edit Request to Add Section: Product and Pipeline:
Aerie Pharmaceuticals is building a global pipeline of products and product candidates, comprising drugs and drug delivery systems, focused initially on glaucoma, dry eye and retinal diseases. (https://aeriepharma.com/rd/pipeline/)

(https://aeriepharma.com/rd/pipeline/)

INCLUDE PIPELINE IMAGE

RHOPRESSA® (netarsudil ophthalmic solution)

(https://rhopressa.com/hcp/)

Rhopressa® was approved by the FDA in December 2017. (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208254Orig1s000TOC.cfm)

Rhopressa® is a prescription eye medication that lowers elevated eye pressure by suppressing the "Rho kinase" (ROCK) enzymes responsible for the buildup of fluid and the increase in intraocular pressure

(IOP). This improves the drainage of fluid within the inner eye, which reduces pressure. Once-daily Rhopressa® is an FDA-approved treatment that lowers eye pressure in patients with open-angle glaucoma and ocular hypertension. (https://glaucoma.org/new-drug-rhopressa-now-available-for-open-angle-glaucoma/)

ROCKLATAN®/ROCLANDA® (netarsudil/latanoprost ophthalmic solution)

Rocklatan® is approved as “Roclanda®” in Europe.

(https://rocklatan.com/hcp/)

Rocklatan® was approved by the FDA in March 2019. (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208259Orig1s000TOC.cfm)

Rocklatan® is a once-daily eye drop that is a fixed-dose combination of latanoprost, the most widely prescribed prostaglandin analog (PGA), and netarsudil, the active ingredient in Rhopressa® (netarsudil ophthalmic solution) 0.02%, a first-in-class Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. The diseased trabecular meshwork is considered to be the main cause of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Rhopressa® works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through a secondary mechanism known as the uveoscleral pathway. (https://glaucoma.org/fda-approves-rocklatan-eye-drop-for-open-angle-glaucoma/) SKM.SamBrown (talk) 17:47, 30 August 2022 (UTC)